Skip to content

Study · Randomized controlled trial · n = 43 · 1993

8 results

Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone.

Neyzi O, Yordam N, Ocal G, Bundak R, Darendeliler F, Açikgöz E, Berberoğlu M, Günöz H, Saka N, Calikoğlu AS

Acta paediatrica (Oslo, Norway : 1992). Supplement1 Mar 1993Cited by 6 (Europe PMC)

PMID8329826 (opens in a new tab)DOI10.1111/j.1651-2227.1993.tb12828.x (opens in a new tab)PepBankPUB-08329826
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In 43 prepubertal children with hypothalamic GH deficiency, height velocity rose by 2 cm/year or more in all except two children across the GHRH(1-29)-NH2 and GH arms.

    In plain wordsIn children with growth hormone deficiency, height growth rose by at least 2 cm a year in all but two children across all groups.

    Peptide
    Sermorelin
    Outcome
    IncreaseHeight velocity increase of 2 cm/year or more
    Study

    n = 43

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    30 and 60 micrograms/kg/day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    An increase in height velocity of 2 cm/year or more was observed in all except two children.
    1 context sentence
    Summary · context
    43 prepubertal children aged between 4.3 and 18.9 years (mean 10.4 +/- 2.9 years) were randomly assigned to three treatment regimens: low-dose GHRH(1-29)-NH2 (LD group; n = 15), high-dose GHRH(1-29)-NH2 (HD group; n = 12) and GH (GH group; n = 16).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In children with hypothalamic GH deficiency, height velocity was lowest in the low-dose GHRH(1-29)-NH2 group compared with the high-dose and GH groups.

    In plain wordsIn children with growth hormone deficiency, low-dose GHRH(1-29)-NH2 gave the slowest height growth compared with high-dose GHRH(1-29)-NH2 and with growth hormone.

    Peptide
    Sermorelin
    Outcome
    DecreaseHeight velocity in low-dose GHRH group
    Study

    n = 43

    Comparator
    High-dose GHRH(1-29)-NH2 and GH
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    30 micrograms/kg/day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Height velocity during treatment was lowest in the LD group, but comparable in the HD and GH groups.
    1 context sentence
    Summary · context
    43 prepubertal children aged between 4.3 and 18.9 years (mean 10.4 +/- 2.9 years) were randomly assigned to three treatment regimens: low-dose GHRH(1-29)-NH2 (LD group; n = 15), high-dose GHRH(1-29)-NH2 (HD group; n = 12) and GH (GH group; n = 16).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In children with hypothalamic GH deficiency, height SDS for bone age increased only in the GH-treated group, not with GHRH(1-29)-NH2.

    In plain wordsIn children with growth hormone deficiency, height score for bone age rose only with growth hormone, not with GHRH(1-29)-NH2.

    Peptide
    Sermorelin
    Outcome
    No significant changeChange in height SDS for bone age
    Study

    n = 43

    Comparator
    GH
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    30 and 60 micrograms/kg/day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    An increase in height SDS for bone age occurred only in the GH-treated group.
    1 context sentence
    Summary · context
    43 prepubertal children aged between 4.3 and 18.9 years (mean 10.4 +/- 2.9 years) were randomly assigned to three treatment regimens: low-dose GHRH(1-29)-NH2 (LD group; n = 15), high-dose GHRH(1-29)-NH2 (HD group; n = 12) and GH (GH group; n = 16).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In children with hypothalamic GH deficiency, height velocity with high-dose GHRH(1-29)-NH2 was comparable to that with GH.

    In plain wordsIn children with growth hormone deficiency, high-dose GHRH(1-29)-NH2 gave a height growth rate comparable to growth hormone.

    Peptide
    Sermorelin
    Outcome
    No significant changeHeight velocity in high-dose GHRH group versus GH
    Study

    n: not reported in source

    Comparator
    GH
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    60 micrograms/kg/day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Height velocity during treatment was lowest in the LD group, but comparable in the HD and GH groups.
    1 context sentence
    Summary · context
    43 prepubertal children aged between 4.3 and 18.9 years (mean 10.4 +/- 2.9 years) were randomly assigned to three treatment regimens: low-dose GHRH(1-29)-NH2 (LD group; n = 15), high-dose GHRH(1-29)-NH2 (HD group; n = 12) and GH (GH group; n = 16).
  5. 05HumanRandomized controlled trialActivity measurement

    In children with hypothalamic GH deficiency, low-dose GHRH(1-29)-NH2 treatment primed the GH response to intravenous GHRH(1-29)-NH2, whereas the response decreased in the GH group.

    In plain wordsIn children with growth hormone deficiency, low-dose GHRH(1-29)-NH2 treatment increased later growth hormone responses to GHRH(1-29)-NH2, unlike growth hormone treatment.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH response to intravenous GHRH(1-29)-NH2 after low-dose treatment
    Study

    n: not reported in source

    Comparator
    GH group
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    30 micrograms/kg/day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    GH responses to intravenous GHRH(1-29)-NH2 showed a priming effect of the LD GHRH(1-29)-NH2 treatment, while a decrease in response occurred in the GH-treated group.
    1 context sentence
    Summary · context
    43 prepubertal children aged between 4.3 and 18.9 years (mean 10.4 +/- 2.9 years) were randomly assigned to three treatment regimens: low-dose GHRH(1-29)-NH2 (LD group; n = 15), high-dose GHRH(1-29)-NH2 (HD group; n = 12) and GH (GH group; n = 16).
  6. 06HumanRandomized controlled trialActivity measurement

    In children with hypothalamic GH deficiency, GH levels remained unchanged after a subcutaneous test dose of GHRH(1-29)-NH2 in both the low-dose and high-dose groups.

    In plain wordsIn children with growth hormone deficiency, a test injection of GHRH(1-29)-NH2 did not change growth hormone levels in either dose group.

    Peptide
    Sermorelin
    Outcome
    No significant changeGH levels after subcutaneous test dose
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    One-third of the daily dose · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Following a subcutaneous test dose of one-third of the daily dose of GHRH(1-29)-NH2, GH levels remained unchanged in both the LD and HD groups.
    1 context sentence
    Summary · context
    43 prepubertal children aged between 4.3 and 18.9 years (mean 10.4 +/- 2.9 years) were randomly assigned to three treatment regimens: low-dose GHRH(1-29)-NH2 (LD group; n = 15), high-dose GHRH(1-29)-NH2 (HD group; n = 12) and GH (GH group; n = 16).
  7. 07HumanRandomized controlled trialPharmacokinetics

    In children with hypothalamic GH deficiency, GHRH immunoreactivity accumulated over time in the high-dose GHRH(1-29)-NH2 group.

    In plain wordsIn children with growth hormone deficiency on high-dose GHRH(1-29)-NH2, GHRH levels in the blood built up over time.

    Peptide
    Sermorelin
    Outcome
    IncreaseGHRH immunoreactivity accumulation in high-dose group
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    60 micrograms/kg/day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    accumulation of GHRH immunoreactivity over time in the HD group
    1 context sentence
    Summary · context
    43 prepubertal children aged between 4.3 and 18.9 years (mean 10.4 +/- 2.9 years) were randomly assigned to three treatment regimens: low-dose GHRH(1-29)-NH2 (LD group; n = 15), high-dose GHRH(1-29)-NH2 (HD group; n = 12) and GH (GH group; n = 16).
  8. 08HumanRandomized controlled trialPharmacokinetics

    In children with hypothalamic GH deficiency, measured GHRH levels did not correlate with GH levels during GHRH(1-29)-NH2 treatment.

    In plain wordsIn children with growth hormone deficiency, GHRH levels in the blood did not match growth hormone levels during GHRH(1-29)-NH2 treatment.

    Peptide
    Sermorelin
    Outcome
    No significant changeCorrelation between measured GHRH and GH levels
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    30 and 60 micrograms/kg/day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    but there was no correlation between measured GHRH and GH levels.(ABSTRACT TRUNCATED AT 250 WORDS)
    1 context sentence
    Summary · context
    43 prepubertal children aged between 4.3 and 18.9 years (mean 10.4 +/- 2.9 years) were randomly assigned to three treatment regimens: low-dose GHRH(1-29)-NH2 (LD group; n = 15), high-dose GHRH(1-29)-NH2 (HD group; n = 12) and GH (GH group; n = 16).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.